# US 2026/0062427 A1 · Bicyclic Ureas As Kinase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062427 A1
- Document ID: US20260062427A1
- Status: Published application
- Kind: A1
- Application number: 19/317,573
- Filed: 2025-09-03
- Published: 2026-03-05
- Earliest claimed: 2024-09-03
- Applicants: Incyte Corporation
- Inventors: Charles Cole; Brent Douty; Oleg Vechorkin; Eddy W. Yue
- Web page: https://patentgrep.com/patent/US20260062427A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07B 59/002: {Heterocyclic compounds}
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
X is NR4 or CR5R6;
Y is absent, or CR7R8
R1 is selected from C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R1 are each optionally substituted with 1, 2, or 3 independently selected R1A substituents;
each R1A is independently selected from halo, oxo, CN, NO2, ORa11, SRa11, NHORa11, C(O)Rb11, C(O)NRc11Rd11, C(O)NRc11(ORa11), C(O)ORa11, OC(O)Rc11, OC(O)NRc11Rd11, NRc11Rd11, NRc11NRc11Rd11, NRc11C(O)Rb11, NRc11C(O)ORa11, NRc11C(O)NRc11Rd11, C(═NRc11)Rb11, C(═NRc11)NRc11Rd11, NRc11C(═NRc11)NRc11Rd11, NRc11C(═NRc11)Rb11, NRc11S(O)Rb11, NRc11S(O)NRc11Rd11, NRc11S(O)2Rb11, NRc11S(O)(═NRc11)Rb11, NRc11S(O)2NRc11Rd11, S(O)Rb11, S(O)NRc11Rd11, S(O)2Rb11, S(O)2NRc11Rd11, OS(O)(═NRc11)Rb11, and OS(O)2Rb11;
each Ra11, Rb111, Rc11, and Rd11 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra11, Rb11, Rc11 and Rd11 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Rc11 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
Cy2 is selected from C3-10 cycloalkyl and 4-12 membered heterocycloalkyl, wherein the C3-10 cycloalkyl and 4-12 membered heterocycloalkyl are each substituted with 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2 substituents;
each R2 is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)NRc2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2 NRc2NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(═NRc2)Rb2, C(═NRc2)NRc2Rd2, NR2C(═NRc2)NRc2Rd2, NRc2C(═NRc2)Rb2, NRc2S(O)Rb2, NRc2S(O)NRc2Rd2, NRc2S(O)2Rb2, NRc2S(O)(═NRc2)Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2 S(O)2NRc2Rd2, OS(O)(═NRc2)Rb2, OS(O)2Rb2, SF5, P(O)Rf2Rg2, OP(O)(ORh2)(ORi2), P(O)(ORh2)(ORi2), and BRj2Rk2, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
each Ra2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra2, Rc2 and Rd2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
or, any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R2A substituents;
each Rb2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rb2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2A substituents;
each Rc2 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-;
each Rf2 and Rg2 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-;
each Rh2 and Ri2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-;
each Rj2 and Rk2 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
or any Rj2 and Rk2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl;
each R2A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa21, SRa21, NHORa21, C(O)Rb21, C(O)NRc21Rd21, C(O)NRc21(ORa21), C(O)ORa21, OC(O)Rb21, OC(O)NRc21Rd21, NRc21Rd21, NRc21NRc21Rd21, NRc21C(O)Rb21, NRc21C(O)ORa21, NRc21C(O)NRc21Rd21, C(═NRc21)Rb21, C(═NRc21)NRc21Rd21, NRc21C(═NRc211Rc21Rd21, NRc21C(═NRc21)Rb21, NRc21S(O)Rb21, NRc21S(O)NRc21Rd21, NRc21S(O)2Rb21, NRc21S(O)(═NRc21)Rb21 NRc21S(O)2NRc21Rd21 S(O)Rb21, S(O)NRc21Rd21, S(O)2Rb21, S(O)2NRc21Rd21 OS(O)(═NRc21)Rb21 OS(O)2Rb21, SF5, P(O)Rf21Rg21, OP(O)(ORh21)(ORi21), P(O)(ORh21)(ORi21), and BRj21R11, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R2A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2B substituents;
each Ra21, Rc21, and Rd21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra21, Re21 and Rd21 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2B substituents;
or, any Rc21 and Rd21 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R2B substituents;
each Rb21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Rb21 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R2B substituents;
each Rc21 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-;
each Rf21 and Rg21 is independently selected from H, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-;
each Rh21 and Ri21 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C16 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-;
each Rj21 and Rk21 is independently selected from OH, C1-6 alkoxy, and C1-6 haloalkoxy;
or any Rj21 and Rk21 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl and C1-6 haloalkyl;
each R2B is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa22, SRa22, NHORa22, C(O)Rb22, C(O)NRc22Rd22, C(O)NRc22(ORa22), C(O)ORa22, OC(O)Rb22, OC(O)NRc22Rd22, NRc22Rd22 NRc22NRc22Rd22, NR22C(O)Rb22, NRc22C(O)ORa22, NRc22C(O)—NRc22Rd22, C(═NRc22)Rb22, C(═NRc22)Rc22Rd22, NRc22C(═NRc22NRc22Rd22, NR22C(═NRc22)Rb22, NRc22S(O)Rb22, NR22S(O)NRc22Rd22, NRc22S(O)2Rb22, NRc22S(O)(═NRc22)Rb22, NRc22S(O)2NRc22Rd22, S(O)Rb22, S(O)NRc22Rd22, S(O)2Rb22, S(O)2NRc22Rd22, OS(O)(═NRc22)Rb22, and OS(O)2Rb22, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R2′ are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Ra22, Rc22, and Rd22 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Ra22, Rc22 and Rd22 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, any Rc22 and Rd22 attached to the same N atom, together with the N atom to which they are attached, form a 5-6 membered heteroaryl or a 4-7 membered heterocycloalkyl group, wherein the 5-6 membered heteroaryl or 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Rb22 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of Rb22 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Rc22 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
R3A is selected H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R3B is selected C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl;
or, R3A and R3B, together with the C atom to which they are attached, form a C3-7 cycloalkyl group, wherein the C3-7 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R4 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R4A substituents;
each R4A is independently selected from halo, oxo, CN, NO2, ORa4, SRa4, NHORa4, C(O)Rb4, C(O)NRc4Rd4, C(O)NRc4(ORa4), C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4 NRc4NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, C(═NRc4)Rb4, C(═NRc4)NRc4Rd4, NRc4C(═NRc4)NRc4Rd4, NRc4C(═NRc4)Rb4, NRc4S(O)Rb4, NRc4S(O)NRc4Rd4 NRc4S(O)2Rb4, NRc4S(O)(═NRc4)Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, S(O)2NRc4Rd4, OS(O)(═NRc4)Rb4, and OS(O)2Rb4;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of Ra4, Rb4, Rc4 and Rd4 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Rc4 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl;
R5 and R6 are each independently selected from H, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R5 or R6 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, R5 and R6, together with the C atom to which they are attached, form a C3-10 cycloalkyl group, wherein the C3-10 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R7 and R8 are each independently selected from H, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R7 or R8 are each optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
or, R7 and R8, together with the C atom to which they are attached, form a C3-10 cycloalkyl group, wherein the C3-10 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R9 is selected from H, halo, CN, C(O)OH, NH2, NO2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9 are optionally substituted with 1, 2, 3, or 4 independently selected R9A substituents;
each R9A is independently selected from halo, oxo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl-, CN, NO2, ORa91, SRa91, NHORa91, C(O)Rb91, C(O)NRc91Rd91, C(O)NRc91(ORa91), C(O)ORa91, OC(O)Rb91, OC(O)NRc91Rd91 NRc91Rd91, NRc91NRc91Rd91, NRc91C(O)Rb91, NRc91C(O)ORa91, NRc91C(O)NRc91Rd91, C(═NRc91)Rb91, C(═NRc91)NRc91Rd91, NRc91C(═NRc91)Rc91Rd91, NRc91(═NRc91)Rb91, NRc91S(O)Rb91, NRc91S(O)NRc91Rd91, NRc91S(O)2Rb91, NRc91S(O)(═NRc91)Rb91, NRc91S(O)2NRc91Rd91 S(O)Rb91, S(O)NRc91Rd91, S(O)2Rb91, S(O)2NRc91Rd91 OS(O)(═NRc91)Rb91, OS(O)2Rb91, and SF5, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R9A are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Ra91, Rc91, and Rd91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of Ra91, Rc91 and Rd91 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
or, any Rc91 and Rd91 attached to the same N atom, together with the N atom to which they are attached, form a 5-10 membered heteroaryl or a 4-10 membered heterocycloalkyl group, wherein the 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
each Rb91 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected RM substituents;
each Rc91 is independently selected from H, OH, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-; and
each RM is independently selected from OH, halo, oxo, CN, C(O)OH, NH2, NO2, SF5, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is trideuteromethyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy2 is C3-10 cycloalkyl, which is substituted with 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2 substituents.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy2 is cyclopentyl or deuterocyclopentyl, wherein the cyclopentyl and deuterocyclopentyl are each substituted with 1 or 2 independently selected R2 substituents.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R2 is independently selected from NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2; and
each Ra2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R2 is independently selected from NHC(O)OCH3.

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3A and R3B, together with the C atom to which they are attached, form a C3-7 cycloalkyl group, wherein the C3-7 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3A and R3B, together with the C atom to which they are attached, form a cyclopropyl, methylcyclopropyl, cyclobutyl, fluorocyclobutyl, or cyclopentyl group.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is NR4;
R4 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R4A substituents;
each R4A is independently selected from halo, CN, and ORa4; and
each Ra4 is independently selected from H and C1-6 alkyl.

### Claim at position 15

16-17. (canceled)

### Claim 18 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted with 1, 2, 3, or 4 independently selected R4A substituents;
each R4A is independently selected from halo, CN, and ORa4; and
each Ra4 is independently selected from H and C1-6 alkyl.

### Claim 19 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from H, methyl, trideuteromethyl, ethyl, trifluoroethyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, and tetrahydropyranylmethyl, wherein the methyl, ethyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, and tetrahydropyranylmethyl of R4 are each optionally substituted with 1, 2, 3, or 4 independently selected R4A substituents,
each R4A is independently selected from halo, CN, and ORa4; and
each Ra4 is independently selected from H and C1-6 alkyl.

### Claim at position 18

20-21. (canceled)

### Claim 22 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from H, methyl, trideuteromethyl, ethyl, trifluoroethyl, methoxyethyl, cyclopropylmethyl, (cyanocyclobutyl)methyl, (difluorocyclohexyl)methyl, and tetrahydropyranylmethyl.

### Claim 23 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X is CR5R6; and
R5 and R6 are each independently selected from H, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C1-6 haloalkyl;
or, R5 and R6, together with the C atom to which they are attached, form a C3-7 cycloalkyl group, wherein the C3-7 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents.

### Claim at position 21

24-25. (canceled)

### Claim 26 (depends on 23)

The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R5 and R6 are each independently selected from H and methyl;
or, R5 and R6, together with the C atom to which they are attached, form a cyclopropyl group.

### Claim 27 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is absent or CR7R8; and
R7 and R8 are each independently selected from H, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C1-6 haloalkyl.

### Claim at position 24

28-30. (canceled)

### Claim 31 (depends on 27)

The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R7 and R8 are each independently selected from H, oxo, methyl, and trifluoromethyl.

### Claim at position 26

32-33. (canceled)

### Claim 34 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R9 is selected from H and methyl.

### Claim 35 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X is NR4 or CR5R6;
Y is absent, or CR7R8
R1 is selected from C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl;
Cy2 is C3-10 cycloalkyl, which is substituted with 1, 2, 3, 4, 5, 6, 7 or 8 independently selected R2 substituents;
each R2 is independently selected from NRc2C(O)Rb2, NRc2C(O)ORa2, and NRc2C(O)NRc2Rd2;
each Ra2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
R3A is selected H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C1-6 alkyl-, C3-7 cycloalkyl-C1-6 alkyl-, (5-6 membered heteroaryl)-C1-6 alkyl-, and (4-7 membered heterocycloalkyl)-C1-6 alkyl-;
R3B is selected C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl;
or, R3A and R3B, together with the C atom to which they are attached, form a C3-7 cycloalkyl group, wherein the C3-7 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R4 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (5-10 membered heteroaryl)-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R4A substituents;
each R4A is independently selected from halo, CN, and ORa4;
each Ra4 is independently selected from H and C1-6 alkyl;
R5 and R6 are each independently selected from H, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C1-6 haloalkyl;
or, R5 and R6, together with the C atom to which they are attached, form a C3-7 cycloalkyl group, wherein the C3-7 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R7 and R8 are each independently selected from H, oxo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C1-6 haloalkyl;
R9 is selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl; and
each RM is independently selected from OH, halo, oxo, CN, C(O)OH, NH2, NO2, SF5, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl.

### Claim 36 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
X is NR4 or CR5R6;
Y is absent, or CR7R8
R1 is C1-3 alkyl;
Cy2 is C3-7 cycloalkyl, which is substituted with 1 or 2 independently selected R2 substituents;
each R2 is independently selected from NRc2C(O)ORa2;
each Ra2 and Rc2 is independently selected from H and C1-6 alkyl;
R3A and R3B, together with the C atom to which they are attached, form a C3-7 cycloalkyl group, wherein the C3-7 cycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected RM substituents;
R4 is selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl-, wherein the C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl-C1-6 alkyl-, and (4-10 membered heterocycloalkyl)-C1-6 alkyl- of R4 are each optionally substituted with 1, 2, 3, or 4 independently selected R4A substituents;
each R4A is independently selected from halo, CN, and ORa4;
each Ra4 is independently selected from H and C1-6 alkyl;
R5 and R6 are each independently selected from H and C1-6 alkyl;
or, R5 and R6, together with the C atom to which they are attached, form a C3-7 cycloalkyl group;
R7 and R8 are each independently selected from H, oxo, C1-6 alkyl, and C1-6 haloalkyl;
R9 is selected from H and C1-6 alkyl; and
each RM is independently selected from OH, halo, CN, NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkoxy, and C1-6 haloalkyl.

### Claim 37 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is a compound of Formula II, a compound of Formula III, a compound of Formula IV, a compound of Formula V, or a compound of Formula VI:
or a pharmaceutically acceptable salt thereof.

### Claim at position 31

38-41. (canceled)

### Claim 42 (depends on 1)

The compound of claim 1, which is selected from:
methyl ((1R,3R)-3-(6-((1-(1-carbamoylcyclobutyl)-3,3-dimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((1′-(1-carbamoylcyclobutyl)-2′-oxo-1′,2′-dihydrospiro[cyclopropane-1,3′-pyrrolo[2,3-b]pyridin]-6′-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((8-(1-carbamoylcyclobutyl)-7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((1-(1-carbamoylcyclobutyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-7-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((1-(1-carbamoylcyclobutyl)-3-methyl-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-7-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((1-(1-carbamoylcyclobutyl)-3-(2-methoxyethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-7-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((1-(1-carbamoylcyclobutyl)-3-(cyclopropylmethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-7-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((1-(1-carbamoylcyclobutyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-7-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((3-(1-carbamoylcyclobutyl)-1-((1-cyanocyclobutyl)methyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((3-(1-carbamoylcyclobutyl)-1-((4,4-difluorocyclohexyl)methyl)-7-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
methyl ((1R,3R)-3-(6-((3-(1-carbamoylcyclobutyl)-7-methyl-2-oxo-1-((tetrahydro-2H-pyran-4-yl)methyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate; and
methyl ((1R,3R)-3-(6-((3-(1-carbamoylcyclobutyl)-7-methyl-1-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl)amino)-3-(methyl-d3)-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)cyclopentyl-1-d)carbamate;
or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is deuterated.

### Claim 44 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 45

(canceled)

### Claim 46 (depends on 1)

A method of treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 37

47-49. (canceled)

### Claim 50 (depends on 1)

A method of treating a myeloproliferative disorder in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 51

(canceled)

### Claim 52 (depends on 1)

A method of treating myelodysplastic syndrome in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
